FDA Expands Indication for Nilotinib.
The FDA expanded the indication for nilotinib for the treatment of children with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase who are at least a year old, as well as those who are resistant to or cannot tolerate imatinib. The drug is the third tyrosine kinase inhibitor approved for children with this rare cancer.